California’s
$3 billion stem cell agency has called a high-level meeting for next fall to
examine a
"red-hot" issue that many prominent researchers say could lead ultimately to alteration of the human race.
"red-hot" issue that many prominent researchers say could lead ultimately to alteration of the human race.
The topic is a technique that makes it much easier
to alter the genetic make-up of individuals in a way that can be inherited by
their offspring.
In April,
scientists in China reported genetically modifying human embryos in what was
regarded as a “world first.” (See here and here.)
That came
after a group of leading scientists in March called for a global moratorium on the genome-editing practice, stating that the therapeutic benefits were tenuous.
More
recently Marcy Darnovsky, executive director of the Center for Genetics and
Society in Berkeley, wrote on May 28 about how the subject was viewed at a
meeting called, “Biotech and the Ethical Imagination: A Global Summit.”
 |
| Steven Pinker |
“The far end of techno-enthusiastic perspectives, both on human germline modification specifically and on biotech in general, was represented by Harvard experimental psychologist and popular science writer Steven Pinker. In his opening remarks, Pinker counseled bioethicists to ‘stay out of the way of progress.’ In his closing comments, he cast ‘vague fears’ as standing in the way of saving millions of lives. In between, he epitomized the ‘bad boy scientism’ that too frequently characterizes the biotech field.”
Jonathan
Thomas, chairman of the stem cell agency, and Geoff Lomax, the agency’s main
person on bioethics, wrote on June 1 about the matter and the upcoming meeting.
In an item on the agency’s Stem Cellar blog, they said,
“Given CIRM’s support for research activities where genome editing may be employed, we believe it is important to have effective policies to guide our future funding decisions. Therefore, we have charged the CIRM Medical and Ethical Standards Working Group with convening a public workshop to elucidate the scientific and policy considerations surrounding genome editing in the context of CIRM supported research. This workshop is a first step in evaluating whether CIRM should make changes to its existing policies governing stem cell research.”
CIRM’s
standards group consists of some of the top bioethicists in the country. Early
on, they developed the agency’s rules for research on stem cells, which were
the most advanced in the country at the time. The chairman of the group is
Bernie Lo of UC San Francisco.
The genome-editing issue to
be discussed in November was originally scheduled to be brought up at an April
meeting of the standards group. However, it was put off for a variety of reasons. Thomas subsequently
called the meeting for next fall.
At the April
meeting, Ted Peters of the Pacific Lutheran Theological Seminary and a member
of the stem cell standards group, said the issue was “red hot.” Jeff Sheehy, a member of the agency board and
a communications manager at UC San Francisco, said the agency needed to clarify
where it stood.
Robert
Taylor of the Emory School of Medicine and also a member of the standards
group, said,
“There are companies that are offering to do this for your cell line, so it's really out there.”
Lo said,
“I think Jeff has raised a really important, complex and breaking topic. I think the idea of having a symposium to deal with both the science, and the ethics policy could be a really important thing to do.”Suggestions regarding the meeting can be sent to Lomax at glomax@cirm.ca.gov.
